2020 IPO

Annexon Biosciences Stock

Biotechnology company developing therapeutics for neurodegenerative and autoimmune disorders

Sign up today and learn more about Annexon Biosciences Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Annexon Biosciences Stock

Annexon Biosciences is the development of therapeutic products that halt the progression of complement-mediated neurodegeneration (CMND).

Funding History

August 2011$1000K
December 2014$34.0M
June 2016$44.0M
December 2018$75.0M


Chief Scientific Officer

Ted Yednock


Arnon Rosenthal

President & Chief Executive Officer

Douglas Love

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 300K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: